• 0Shopping Cart
AmideBio LLC
  • ABOUT
    • CONTACT
    • NEWS
    • Intellectual Property
  • TEAM
    • Management and Operations
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisory Board
  • SCIENCE
    • Discovery
    • Manufacturing
    • Therapeutic Pipeline
  • PRODUCTS
    • Amyloid Peptides
    • Amyloid Kits and Buffers
    • Bowman-Birk Inhibitors
    • Brazzeins
    • Proinsulin
    • Toxins and Knottins
    • Custom Product Inquiry
    • Request Quote
  • NEWS
  • SUPPORT
    • CONTACT
    • Frequently Asked Questions
    • Application Notes
    • Inquiry Form
  • My Account
    • Checkout
    • Login
  • Search
  • Menu

AmideBio Announces Addition of Dr. Robert S. Hodges to Scientific Advisory Board

You are here: Home / Privacy Policy / NEWS / AmideBio Announces Addition of Dr. Robert S. Hodges to Scientific Advisory...

AmideBio Announces Addition of Dr. Robert S. Hodges to Scientific Advisory Board

COMPANY NEWS

  • AMIDEBIO Awarded $1.56M SBIR Phase II Grant to Further Development of its Novel Glucagons for the Treatment of Hyperinsulinism2019-09-30 - 07:33

    AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $1.56M in funding through a Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The goal of this two-year grant is to enable an Investigational New Drug (IND) filing with the […]

  • David Brunel Takes Over Chairmanship at AmideBio2018-11-16 - 08:47

    AmideBio LLC, a privately held biopharmaceutical company, announced today that David Brunel, a board member of AmideBio, has assumed the role of Chairman of the Board, replacing Misha Plam. Dr. Plam, a founder of AmideBio who retired recently as President and CEO, is now Chairman Emeritus. Read the full press release.

  • Diabetes Industry Veteran Pawel Fludzinski, Ph.D. assumed role of Company President of AmideBio2018-09-03 - 22:37

    AmideBio LLC, a privately held biopharmaceutical company, announced today that Pawel Fludzinski, Ph.D. has assumed the role of Company President in addition to Chief Executive Officer, effective immediately. Dr. Misha Plam is retiring from the role but will remain Chairman of the Board of Directors. Read the full press release.

Scroll to top